Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia.
Pallarès V, Hoyos M, Chillón MC, Barragán E, Prieto Conde MI, Llop M, Falgàs A, Céspedes MV, Montesinos P, Nomdedeu JF, Brunet S, Sanz MÁ, González-Díaz M, Sierra J, Mangues R, Casanova I. Pallarès V, et al. Among authors: hoyos m. Cancers (Basel). 2018 Nov 13;10(11):436. doi: 10.3390/cancers10110436. Cancers (Basel). 2018. PMID: 30428571 Free PMC article.
NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients.
Pallarès V, Hoyos M, Chillón MC, Barragán E, Conde MIP, Llop M, Céspedes MV, Nomdedeu JF, Brunet S, Sanz MÁ, González-Díaz M, Sierra J, Casanova I, Mangues R. Pallarès V, et al. Among authors: hoyos m. Oncotarget. 2017 Jun 16;8(44):76003-76014. doi: 10.18632/oncotarget.18537. eCollection 2017 Sep 29. Oncotarget. 2017. PMID: 29100287 Free PMC article.
CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia.
Barragán E, Chillón MC, Castelló-Cros R, Marcotegui N, Prieto MI, Hoyos M, Pippa R, Llop M, Etxabe A, Cervera J, Rodríguez G, Buño I, Rifón J, Sierra J, González M, Calasanz MJ, Sanz MA, Odero MD. Barragán E, et al. Among authors: hoyos m. Haematologica. 2015 May;100(5):e183-5. doi: 10.3324/haematol.2014.118117. Epub 2015 Jan 30. Haematologica. 2015. PMID: 25637054 Free PMC article. No abstract available.
Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.
Nomdedéu JF, Esquirol A, Carricondo M, Pratcorona M, Hoyos M, Garrido A, Rubio M, Bussaglia E, García-Cadenas I, Estivill C, Brunet S, Martino R, Sierra J. Nomdedéu JF, et al. Among authors: hoyos m. Biol Blood Marrow Transplant. 2018 Jan;24(1):55-63. doi: 10.1016/j.bbmt.2017.09.001. Epub 2017 Sep 20. Biol Blood Marrow Transplant. 2018. PMID: 28939453 Free article.
Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5-azacytidine: Identification of responding patients.
Santaliestra M, Garrido A, Carricondo M, Bussaglia E, Pratcorona M, Blanco ML, Gich I, Hoyos M, Esquirol A, García-Cadenas I, Brunet S, Martino R, Sierra J, Nomdedéu JF. Santaliestra M, et al. Among authors: hoyos m. Eur J Haematol. 2019 Sep;103(3):208-214. doi: 10.1111/ejh.13275. Epub 2019 Jul 3. Eur J Haematol. 2019. PMID: 31211880
The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
Díaz-Beyá M, Brunet S, Nomdedéu J, Pratcorona M, Cordeiro A, Gallardo D, Escoda L, Tormo M, Heras I, Ribera JM, Duarte R, de Llano MP, Bargay J, Sampol A, Nomdedeu M, Risueño RM, Hoyos M, Sierra J, Monzo M, Navarro A, Esteve J; Cooperative AML group CETLAM. Díaz-Beyá M, et al. Among authors: hoyos m. Oncotarget. 2015 Oct 13;6(31):31613-27. doi: 10.18632/oncotarget.5148. Oncotarget. 2015. PMID: 26436590 Free PMC article.
Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment size.
Nomdedeu J, Bussaglia E, Villamor N, Martinez C, Esteve J, Tormo M, Estivill C, Queipo MP, Guardia R, Carricondo M, Hoyos M, Llorente A, Juncà J, Gallart M, Domingo A, Bargay J, Mascaró M, Moraleda JM, Florensa L, Ribera JM, Gallardo D, Brunet S, Aventin A, Sierra J; Spanish CETLAM. Nomdedeu J, et al. Among authors: hoyos m. Leuk Res. 2011 Feb;35(2):163-8. doi: 10.1016/j.leukres.2010.05.015. Epub 2010 Jun 9. Leuk Res. 2011. PMID: 20542566 Clinical Trial.
Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1.
Oñate G, Bataller A, Garrido A, Hoyos M, Arnan M, Vives S, Coll R, Tormo M, Sampol A, Escoda L, Salamero O, Garcia A, Bargay J, Aljarilla A, Nomdedeu JF, Esteve J, Sierra J, Pratcorona M. Oñate G, et al. Among authors: hoyos m. Blood Adv. 2022 Feb 8;6(3):882-890. doi: 10.1182/bloodadvances.2020004136. Blood Adv. 2022. PMID: 34516636 Free PMC article.
Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML.
Nomdedéu JF, Hoyos M, Carricondo M, Bussaglia E, Estivill C, Esteve J, Tormo M, Duarte R, Salamero O, de Llano MP, García A, Bargay J, Heras I, Martí-Tutusaus JM, Llorente A, Ribera JM, Gallardo D, Aventin A, Brunet S, Sierra J; CETLAM Group. Nomdedéu JF, et al. Among authors: hoyos m. Leukemia. 2013 Nov;27(11):2157-64. doi: 10.1038/leu.2013.111. Epub 2013 Apr 15. Leukemia. 2013. PMID: 23584566
161 results